z-logo
Premium
Justification for a Fixed Dose of Eflapegrastim, a Long‐Acting G‐CSF, in Patients Receiving Docetaxel‐Cyclophosphamide Chemotherapy
Author(s) -
Barrett John A.,
Greene Douglas,
Lakshmikanthan Sribalaji,
Kolli Prasad,
Chawla Shanta,
Lebel Francois
Publication year - 2021
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1723
Subject(s) - pegfilgrastim , docetaxel , cyclophosphamide , medicine , granulocyte colony stimulating factor , neutropenia , chemotherapy , pharmacokinetics , filgrastim , absolute neutrophil count , pharmacology , gastroenterology , urology
Eflapegrastim (Rolontis) is a long‐acting granulocyte colony‐stimulating factor (G‐CSF) produced by conjugating a human G‐CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker. Weight‐based doses of 45 to 270 μg/kg eflapegrastim (12.3‐73.6 μg/kg as G‐CSF) were evaluated in a phase 2 study in patients. Based on these results, a fixed dose of 13.2 mg eflapegrastim (3.6 mg G‐CSF) was compared with pegfilgrastim (6 mg G‐CSF) in 2 phase 3 studies and in a pharmacokinetic single‐arm multicenter study. Absolute neutrophil count (ANC) data from these 3 studies were evaluated in patients with early‐stage breast cancer who were treated with docetaxel and cyclophosphamide (n = 669). Serum concentrations of eflapegrastim were determined by enzyme‐linked immunosorbent assay. Eflapegrastim systemic exposures were higher in cycle 1 than in cycle 3, likely attributable to the higher ANC in cycle 3, increasing neutrophil‐mediated clearance. Eflapegrastim elicited a greater effect on ANC than pegfilgrastim in patients at ∼60% of the G‐CSF dose. Body weight had no clinically significant effect on response, justifying administration of a fixed dose of eflapegrastim. The results from 2 phase 3 studies demonstrate that eflapegrastim at a fixed dose of 13.2 mg (3.6 mg G‐CSF) administered once per chemotherapy cycle is effective in prophylactic treatment of chemotherapy‐induced neutropenia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here